Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINORE: Evaluating B Cell Levels in Infants Exposed to Ocrelizumab During Pregnancy
NCT04998812Phase 4Completed
- Sponsor
- Roche
- Start
- Apr 2022
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 4, open-label trial of ocrelizumab in multiple sclerosis (MS) and clinically isolated syndrome (CIS) (2 arms), sponsored by Roche. Primary endpoint: Percentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN) at 6 weeks. Started Apr 2022; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on NCT04998812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04998812.